Bis(diphenylphosphino)amines-containing ruthenium cymene complexes as potential anti-Mycobacterium tuberculosis agents. Silva, J. P. d., Silva, I. C., Pavan, F. R., Back, D. F., & Araujo, M. P. d. Journal of Inorganic Biochemistry, 173:134–140, 2017. Publisher: Elsevier Inc![Bis(diphenylphosphino)amines-containing ruthenium cymene complexes as potential anti-Mycobacterium tuberculosis agents [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Several ruthenium complexes have been investigated regarding anti-Mycobacterium tuberculosis (anti-MTb) activity, with some diphosphine-containing ruthenium complexes comparable to first and second line drugs. However, to the best of our knowledge, there is no P–N–P-containing ruthenium complexes applied as metallodrugs. Thus, this study focused on the synthesis, characterization and anti-MTb activity of a new series of coordination compounds with general formula [RuCl(η6-p-cymene)(P–NR–P)]X (R = CH2Py (Py = pyridine) − [1a], CH2Ph (Ph = phenyl) − [1b], Ph − [1c] and p-tol (p-tol = p-tolyl) − [1d]; X = PF6− or BF4−). The complexes were fully characterized by NMR (1H, 31P\1H\), vibrational spectroscopy (FTIR), ESI-MS, molar conductance, elemental analysis and X-ray diffraction studies. The molecular structures of [1a][rad]PF6, [1c][rad]BF4 and [1d][rad]PF6 were determined and confirm the spectroscopic and ESI-MS data. The complexes were used in anti-MTb trials, and the preliminary results are presented. The complexes are promising anti-MTb agents with MIC90 (Minimum Inhibitory Concentration of compounds required to inhibit the growth of 90% of MTb) values comparable with the Ethambutol, the reference drug used in this work, and complex [1a][rad]BF4 presented the highest selectivity index.
@article{silva_bisdiphenylphosphinoamines-containing_2017,
title = {Bis(diphenylphosphino)amines-containing ruthenium cymene complexes as potential anti-{Mycobacterium} tuberculosis agents},
volume = {173},
issn = {18733344},
url = {http://dx.doi.org/10.1016/j.jinorgbio.2017.04.008},
doi = {10.1016/j.jinorgbio.2017.04.008},
abstract = {Several ruthenium complexes have been investigated regarding anti-Mycobacterium tuberculosis (anti-MTb) activity, with some diphosphine-containing ruthenium complexes comparable to first and second line drugs. However, to the best of our knowledge, there is no P–N–P-containing ruthenium complexes applied as metallodrugs. Thus, this study focused on the synthesis, characterization and anti-MTb activity of a new series of coordination compounds with general formula [RuCl(η6-p-cymene)(P–NR–P)]X (R = CH2Py (Py = pyridine) − [1a], CH2Ph (Ph = phenyl) − [1b], Ph − [1c] and p-tol (p-tol = p-tolyl) − [1d]; X = PF6− or BF4−). The complexes were fully characterized by NMR (1H, 31P\{1H\}), vibrational spectroscopy (FTIR), ESI-MS, molar conductance, elemental analysis and X-ray diffraction studies. The molecular structures of [1a][rad]PF6, [1c][rad]BF4 and [1d][rad]PF6 were determined and confirm the spectroscopic and ESI-MS data. The complexes were used in anti-MTb trials, and the preliminary results are presented. The complexes are promising anti-MTb agents with MIC90 (Minimum Inhibitory Concentration of compounds required to inhibit the growth of 90\% of MTb) values comparable with the Ethambutol, the reference drug used in this work, and complex [1a][rad]BF4 presented the highest selectivity index.},
journal = {Journal of Inorganic Biochemistry},
author = {Silva, Juliana P. da and Silva, Isabel C. and Pavan, Fernando R. and Back, Davi F. and Araujo, Márcio P. de},
year = {2017},
pmid = {28521188},
note = {Publisher: Elsevier Inc},
pages = {134--140},
}
Downloads: 0
{"_id":"FxPRXXrkDNBJ4sboh","bibbaseid":"silva-silva-pavan-back-araujo-bisdiphenylphosphinoaminescontainingrutheniumcymenecomplexesaspotentialantimycobacteriumtuberculosisagents-2017","author_short":["Silva, J. P. d.","Silva, I. C.","Pavan, F. R.","Back, D. F.","Araujo, M. P. d."],"bibdata":{"bibtype":"article","type":"article","title":"Bis(diphenylphosphino)amines-containing ruthenium cymene complexes as potential anti-Mycobacterium tuberculosis agents","volume":"173","issn":"18733344","url":"http://dx.doi.org/10.1016/j.jinorgbio.2017.04.008","doi":"10.1016/j.jinorgbio.2017.04.008","abstract":"Several ruthenium complexes have been investigated regarding anti-Mycobacterium tuberculosis (anti-MTb) activity, with some diphosphine-containing ruthenium complexes comparable to first and second line drugs. However, to the best of our knowledge, there is no P–N–P-containing ruthenium complexes applied as metallodrugs. Thus, this study focused on the synthesis, characterization and anti-MTb activity of a new series of coordination compounds with general formula [RuCl(η6-p-cymene)(P–NR–P)]X (R = CH2Py (Py = pyridine) − [1a], CH2Ph (Ph = phenyl) − [1b], Ph − [1c] and p-tol (p-tol = p-tolyl) − [1d]; X = PF6− or BF4−). The complexes were fully characterized by NMR (1H, 31P\\1H\\), vibrational spectroscopy (FTIR), ESI-MS, molar conductance, elemental analysis and X-ray diffraction studies. The molecular structures of [1a][rad]PF6, [1c][rad]BF4 and [1d][rad]PF6 were determined and confirm the spectroscopic and ESI-MS data. The complexes were used in anti-MTb trials, and the preliminary results are presented. The complexes are promising anti-MTb agents with MIC90 (Minimum Inhibitory Concentration of compounds required to inhibit the growth of 90% of MTb) values comparable with the Ethambutol, the reference drug used in this work, and complex [1a][rad]BF4 presented the highest selectivity index.","journal":"Journal of Inorganic Biochemistry","author":[{"propositions":[],"lastnames":["Silva"],"firstnames":["Juliana","P.","da"],"suffixes":[]},{"propositions":[],"lastnames":["Silva"],"firstnames":["Isabel","C."],"suffixes":[]},{"propositions":[],"lastnames":["Pavan"],"firstnames":["Fernando","R."],"suffixes":[]},{"propositions":[],"lastnames":["Back"],"firstnames":["Davi","F."],"suffixes":[]},{"propositions":[],"lastnames":["Araujo"],"firstnames":["Márcio","P.","de"],"suffixes":[]}],"year":"2017","pmid":"28521188","note":"Publisher: Elsevier Inc","pages":"134–140","bibtex":"@article{silva_bisdiphenylphosphinoamines-containing_2017,\n\ttitle = {Bis(diphenylphosphino)amines-containing ruthenium cymene complexes as potential anti-{Mycobacterium} tuberculosis agents},\n\tvolume = {173},\n\tissn = {18733344},\n\turl = {http://dx.doi.org/10.1016/j.jinorgbio.2017.04.008},\n\tdoi = {10.1016/j.jinorgbio.2017.04.008},\n\tabstract = {Several ruthenium complexes have been investigated regarding anti-Mycobacterium tuberculosis (anti-MTb) activity, with some diphosphine-containing ruthenium complexes comparable to first and second line drugs. However, to the best of our knowledge, there is no P–N–P-containing ruthenium complexes applied as metallodrugs. Thus, this study focused on the synthesis, characterization and anti-MTb activity of a new series of coordination compounds with general formula [RuCl(η6-p-cymene)(P–NR–P)]X (R = CH2Py (Py = pyridine) − [1a], CH2Ph (Ph = phenyl) − [1b], Ph − [1c] and p-tol (p-tol = p-tolyl) − [1d]; X = PF6− or BF4−). The complexes were fully characterized by NMR (1H, 31P\\{1H\\}), vibrational spectroscopy (FTIR), ESI-MS, molar conductance, elemental analysis and X-ray diffraction studies. The molecular structures of [1a][rad]PF6, [1c][rad]BF4 and [1d][rad]PF6 were determined and confirm the spectroscopic and ESI-MS data. The complexes were used in anti-MTb trials, and the preliminary results are presented. The complexes are promising anti-MTb agents with MIC90 (Minimum Inhibitory Concentration of compounds required to inhibit the growth of 90\\% of MTb) values comparable with the Ethambutol, the reference drug used in this work, and complex [1a][rad]BF4 presented the highest selectivity index.},\n\tjournal = {Journal of Inorganic Biochemistry},\n\tauthor = {Silva, Juliana P. da and Silva, Isabel C. and Pavan, Fernando R. and Back, Davi F. and Araujo, Márcio P. de},\n\tyear = {2017},\n\tpmid = {28521188},\n\tnote = {Publisher: Elsevier Inc},\n\tpages = {134--140},\n}\n\n\n\n","author_short":["Silva, J. P. d.","Silva, I. C.","Pavan, F. R.","Back, D. F.","Araujo, M. P. d."],"key":"silva_bisdiphenylphosphinoamines-containing_2017-1","id":"silva_bisdiphenylphosphinoamines-containing_2017-1","bibbaseid":"silva-silva-pavan-back-araujo-bisdiphenylphosphinoaminescontainingrutheniumcymenecomplexesaspotentialantimycobacteriumtuberculosisagents-2017","role":"author","urls":{"Paper":"http://dx.doi.org/10.1016/j.jinorgbio.2017.04.008"},"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/FRGBergamini","dataSources":["o2mL7kG99iAQPpNRJ"],"keywords":[],"search_terms":["bis","diphenylphosphino","amines","containing","ruthenium","cymene","complexes","potential","anti","mycobacterium","tuberculosis","agents","silva","silva","pavan","back","araujo"],"title":"Bis(diphenylphosphino)amines-containing ruthenium cymene complexes as potential anti-Mycobacterium tuberculosis agents","year":2017}